Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Nurix Therapeutics (NRIX) has granted inducement awards to 13 new employees on March 11, 2025, as approved by the company's Compensation Committee under Nasdaq Listing Rule 5635(c)(4). The awards include:

• Stock options to purchase 157,150 shares with a 10-year term and $13.90 exercise price
• Restricted stock unit awards (RSUs) representing 107,500 shares

The stock options vest over 4 years, with 25% vesting after one year and the remainder vesting monthly. RSUs also vest over 4 years, with 25% vesting on April 30, 2026, and the remainder vesting quarterly. Both awards require continued employment with Nurix for vesting.

Positive

• Company demonstrates growth with hiring of 13 new employees
• Structured equity compensation plan helps attract and retain talent

Negative

• Potential dilution of existing shareholders from new equity grants

SAN FRANCISCO, March 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases, today announced that on March 11, 2025, the company granted inducement awards to thirteen new employees. The grants were made pursuant to Nurix’s 2024 Equity Inducement Plan as an inducement material to the employees’ acceptance of employment with Nurix and were approved by the Compensation Committee of Nurix’s Board of Directors in accordance with Nasdaq Listing Rule 5635(c)(4).

The company granted stock options to purchase an aggregate of 157,150 shares of Nurix common stock and restricted stock unit awards (RSUs) representing an aggregate of 107,500 shares of Nurix common stock.

One fourth of the total number of shares underlying the stock options will vest on the one-year anniversary of the employee’s date of hire and one forty-eighth of the total number of shares underlying the stock options will vest each month thereafter until the stock option is fully vested on the fourth anniversary of the employee’s date of hire, subject to the employee’s continued service with Nurix on each such vesting date. The stock options have a term of ten years and an exercise price of $13.90 per share, which is equal to the closing price of Nurix’s common stock on the grant date as reported by the Nasdaq Global Market.

One fourth of the total number of shares subject to the RSUs will vest on the one-year anniversary of the RSU vesting start date, which is April 30, 2025, subject to the employee’s continued service with Nurix on the vesting date. Thereafter, one sixteenth of the total number of shares subject to the RSUs shall vest quarterly, until the RSU award is fully vested on the fourth anniversary of the vesting start date, subject to the employee’s continued service with Nurix on each such vesting date.

About Nurix Therapeutics, Inc.

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next frontier in innovative drug design aimed at improving treatment options for patients with cancer and inflammatory diseases. Nurix’s wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. Nurix also is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline. Nurix’s partnered drug discovery pipeline consists of preclinical stage degraders of IRAK4 and STAT6, as well as multiple additional programs under collaboration agreements with Gilead Sciences, Inc., Sanofi S.A. and Pfizer Inc., within which Nurix retains certain options for co-development, co-commercialization and profit sharing in the United States for multiple drug candidates. Powered by a fully AI-integrated discovery engine capable of tackling any protein class, and coupled with unparalleled ligase expertise, Nurix’s dedicated team has built a formidable advantage in translating the science of targeted protein degradation into clinical advancements. Nurix aims to establish degrader-based treatments at the forefront of patient care, writing medicine’s next chapter with a new script to outmatch disease. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com.

Contacts:

Investors
Jason Kantor, Ph.D.
Nurix Therapeutics, Inc.
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media
Aljanae Reynolds
Wheelhouse Life Science Advisors
areynolds@wheelhouselsa.com

FAQ

How many shares are included in Nurix Therapeutics (NRIX) March 2025 inducement grants?

The inducement grants include options for 157,150 shares and RSUs for 107,500 shares of Nurix common stock.

What is the exercise price for NRIX stock options granted in March 2025?

The stock options have an exercise price of $13.90 per share, equal to Nurix's closing price on the grant date.

What is the vesting schedule for Nurix's March 2025 RSU grants?

RSUs vest over 4 years: 25% vests on April 30, 2026, followed by quarterly vesting of 1/16th until full vesting in 2029.

How long is the term of NRIX stock options granted in March 2025?

The stock options have a term of 10 years.